Catherine's questions to Altimmune Inc (ALT) leadership • Q1 2025
Question
Catherine of Citizens JMP, on behalf of John Wolleben, asked about the expected speed of action for pemvidutide compared to competitors like survodutide and which biomarkers might show the most change between 24 and 48 weeks.
Answer
An Altimmune executive attributed pemvidutide's superior speed and potency to its 1:1 GLP-1/glucagon ratio, which contains more glucagon than competitors and drives faster liver fat reduction, enabling a 24-week readout. The executive expects biomarker responses, particularly with ELF and FibroScan, to continue improving between the 24-week and 48-week time points, further validating the drug's effect.